每月彙整：六月 2019

Have you ever wondered what should come between salvation and heaven? How does God want you to live in the in-between?

Our heavenly Father designed a unique plan for you before you were even born—and He wants you to pursue it with anticipation and confidence. In this message, Dr. Stanley points us toward the principles God established for abundant life as we seek His will, learn His ways, and engage in His purposes.

繼續閱讀 →

《這就是中國》第23期：複盤英國“脫歐”公投 張維爲解讀西方政治制度困境 繼續閱讀 →

數字台灣HD260 習近平與中共處境 謝金河 明居正 繼續閱讀 →

橫掃全國勝出!紀錄"地表最大規模選舉" 印度狂人莫迪掌人心"愛國心"扭轉選情【消失的國界】 繼續閱讀 →

《#老謝看世界》2019.06.22 貿易戰瞬息萬變 利率倒掛成美股「頭號」風險 華為風暴席捲全球經濟！？謝金河 李鎮宇 程正樺 繼續閱讀 →

Picture a tug-of-war contest. Two sides struggle against each other, straining to gain control. Can both sides win? Of course not—that’s the nature of the game. In this message, Dr. Stanley sheds light on the internal conflict each of us must face: the battle between obeying God or indulging our flesh. It’s a high-stakes struggle with only one winner. But as children of God we’re not left on our own—with the Holy Spirit on our side, we’re each equipped with self-control. Learn how this fruit of the Spirit tips the scales in your favor. 繼續閱讀 →

數字台灣HD259 台灣創新與轉型之路 謝金河 施振榮 繼續閱讀 →

《這就是中國》第22期：張維爲犀利點評中西政治發展理念 一針見血指出西方民主之困局 繼續閱讀 →

全球最熱200里!美中貿易帶動越南崛起 河內豪宅漲到1坪1千3百萬【消失的國界】 繼續閱讀 →

《#老謝看世界》2019.06.15 貿易戰沒有贏家 拿關稅當武器 川普挑戰不可能的任務？ 繼續閱讀 →

Sooner or later, each of us must face the reality that in our own strength we don’t measure up—we’ve all sinned and fallen short most every day of our lives. But the good news is God’s faithfulness to us has never depended on our perfection. In this message, Dr. Stanley explores four ways we experience God’s fidelity in keeping His promises to His children. Relax into the trustworthy character of our heavenly Father—He will never leave or forsake you 繼續閱讀 →

數字台灣HD258 華為IMPACT 謝金河 楊瑞臨 鄭清文 繼續閱讀 →

聯合生物製藥(股)公司(聯生藥)今日宣布，抗皰疹病毒單株抗體藥物UB-621已獲得美國FDA批准在由HSV-2感染所引起之復發型生殖器皰疹 (Recurrent Genital)患者族群上進行臨床第2期試驗: “A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 in Adults with Recurrent Genital HSV-2 Infection”。UB-621可透過和病毒(HSV-1和HSV-2) 外表包膜上gD 蛋白之靶點作高親和力結合的機制1，阻止病毒侵入宿主而抑制感染。 繼續閱讀 →

Taipei, Taiwan, June 10th , 2019 — United BioPharma (UBP) announced the receipt of Investigational New Drug (IND) approval from the U.S. FDA to conduct a phase 2 clinical trial with UB-621 monoclonal antibody for recurrent genital infection caused by Herpes Simplex Virus, type II (HSV-2). UB-621 works to inhibit the infection through high-affinity binding to the same epitope on viral surface envelope gD protein on both type I (HSV-1) and type II (HSV-2) viruses.1 繼續閱讀 →

郭董示警經濟大海嘯將至！華為封殺令 誰的命運大逆轉！？謝金河 孫明德 吳金榮《#老謝看世界》2019.06.08 繼續閱讀 →